Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

被引：1
|
作者：
Rini, Brian I.
Escudier, Bernard
Murphy, Danielle
Wang, Panpan
Tarazi, Jamal Christo
Motzer, Robert J.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Univ Paris Saclay, Gustave Roussy, Med Oncol, Villejuif, France
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Shanghai, Peoples R China
[5] Pfizer Oncol, San Diego, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
    Murphy, Danielle A.
    Rini, Brian I.
    Escudier, Bernard
    Motzer, Robert J.
    Wang, Panpan
    Li, Sherry
    Williams, J. Andrew
    Tarazi, Jamal C.
    Martini, Jean-Francois
    FUTURE ONCOLOGY, 2020, 16 (17) : 1199 - 1210
  • [2] Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results
    Atkins, M. B.
    Plimack, E. R.
    Puzanov, I.
    Fishman, M. N.
    McDermott, D.
    Cho, D. C.
    Vaishampayan, U.
    George, S.
    Olencki, T.
    Tarazi, J.
    Rosbrook, B.
    Fernandez, K.
    Keefe, S.
    Choueiri, T.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
    Atkins, Michael
    Martini, Jean-Francois
    Plimack, Elizabeth
    McDermott, David
    Puzanov, Igor
    Fishman, Mayer
    Cho, Daniel
    Vaishampayan, Ulka
    Rosbrook, Brad
    Fernandez, Kathrine
    Tarazi, Jamal
    George, Saby
    Choueiri, Toni
    CANCER RESEARCH, 2019, 79 (13)
  • [4] Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka N.
    George, Saby
    Olencki, Thomas
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [5] Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma
    Martini, Jean-Fran Comma Cois
    Plimack, Elizabeth R.
    Choueiri, Toni K.
    McDermott, David F.
    Puzanov, Igor
    Fishman, Mayer N.
    Cho, Daniel C.
    Vaishampayan, Ulka
    Rosbrook, Bradley
    Fernandez, Kathrine C.
    Tarazi, Jamal C.
    George, Saby
    Atkins, Michael B.
    CLINICAL CANCER RESEARCH, 2020, 26 (21) : 5598 - 5608
  • [6] Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC)
    Panian, Justine
    Zhong, Caiwei
    Choi, Sharon
    Quinn, Roxanne
    Ferrier, Evan
    Saad, Eddy
    Saliby, Renee Maria
    Malvar, Carmel
    Pal, Sumanta Kumar
    Ebrahimi, Hedyeh
    Ben Tran
    Weickhardt, Andrew James
    Lalani, Aly-Khan A.
    Suarez, Cristina
    de Velasco, Guillermo
    Kanesvaran, Ravindran
    Zarba, Martin
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    Mckay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] First-line avelumab plus axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
    Choueiri, Toni K.
    Larkin, James M. G.
    Oya, Mototsugu
    Thistlethwaite, Fiona C.
    Martignoni, Marcella
    Nathan, Paul D.
    Powles, Thomas
    McDermott, David F.
    Robbins, Paul B.
    Chism, David D.
    Cho, Daniel C.
    Atkins, Michael B.
    Gordon, Michael S.
    Gupta, Sumati
    Uemura, Hirotsugu
    Tomita, Yoshihiko
    Compagnoni, Anna
    Di Pietro, Alessandra
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Outcomes of patients (pts) with advanced renal cell carcinoma (aRCC) treated with cabozantinib (CABO) after lenvatinib plus pembrolizumab (LEN plus PEM).
    Haro-Silerio, Jaime Ivan
    Johns, Andrew
    Moussa, Mohammad Jad
    Wang, Mindy
    Wang, Emily
    Kovitz, Craig A.
    Campbell, Matthew T.
    Jonasch, Eric
    Shah, Amishi Yogesh
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 433 - 433
  • [9] Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma (aRCC) treated with immune checkpoint inhibitors (ICIs)
    Yildirim, Ahmet
    Wei, Mengting
    Liu, Yuan
    Goswamy, Rohit Vivek
    Choi, Yujin
    Brown, Jacqueline T.
    Nazha, Bassel
    Martini, Dylan J.
    Hartman, Caitlin
    McClintock, Greta Russler
    Zhuang, Tony
    Kissick, Haydn
    Harris, Wayne B.
    Carthon, Bradley Curtis
    Kucuk, Omer
    Master, Viraj A.
    Bilen, Mehmet Asim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Discovery and prevalence of cancer-susceptibility germline mutations (Mts) in patients (Pts) with advanced renal cell carcinoma (aRCC).
    Carlo, Maria Isabel
    Mukherjee, Semanti
    Kernel, Yelena
    Zhang, Liying
    Mandelker, Diana
    Vijai, Joseph
    Coskey, Devyn Taylor
    Pradhan, Nisha
    Hyman, David Michael
    Hakimi, A. Ari
    Coleman, Jonathan
    Lee, Chung-Han
    Feldman, Darren R.
    Voss, Martin Henner
    Offit, Kenneth
    Robson, Mark E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345